羟苯磺酸钙联合治疗新生血管性青光眼急性发作的临床研究  

Clinical study of calcium dobesilate combination treatment for acute attack of neovascular glaucoma

作　　者：陈仕建 刘杨[2] Chen Shijian;Liu Yang(Department of Ophthalmology,Xinyang Central Hospital,Xinyang 464000,China;Department of Ophthalmology,Shangqiu First People’s Hospital,Shangqiu 476000,China)

机构地区：[1]信阳市中心医院眼科,信阳464000 [2]商丘市第一人民医院眼科,商丘476000

出　　处：《中华眼外伤职业眼病杂志》2023年第3期212-217,共6页Chinese Journal of Ocular Trauma and Occupational Eye Disease

摘　　要：目的探讨口服羟苯磺酸钙联合激光及康柏西普治疗新生血管性青光眼急性发作的短期临床效果及对血清血管内皮生长因子(VEGF)、内皮素-1(ET-1)表达的影响。方法随机对照研究。信阳市中心医院2020年1月~2021年12月新生血管性青光眼急性发作80例,按照随机数字表法分为对照组和观察组,每组各40例。其中对照组进行虹膜激光、全视网膜光凝联合玻璃体内注射康柏西普治疗,观察组在对照组的治疗基础上口服羟苯磺酸钙治疗。比较两组周边前房深度、眼压及视力变化情况。随访时间为3个月。结果治疗后两组周边前房深度、眼压及视力均优于治疗前(均P<0.05)。治疗后1个月及3个月,观察组周边前房深度均高于对照组(t=2.26、2.05;均P<0.05),眼压均低于对照组(t=11.63、7.38;均P<0.05),视力均优于对照组(t=2.63、5.06;均P<0.05)。观察组治疗总有效率87.50%(35/40)高于对照组的67.50%(27/40)(χ^(2)=4.59,P=0.032)。治疗后两组血清VEGF、ET-1水平均低于治疗前(均P<0.05)。治疗后1个月及3个月,观察组血清VEGF水平均低于对照组(均P<0.05),血清ET-1水平均低于对照组(均P<0.05)。观察组和对照组并发症发生率(12.50%vs 7.50%)比较差异无统计学意义(χ^(2)=0.14,P=0.709)。结论羟苯磺酸钙联合激光及康柏西普治疗新生血管性青光眼急性发作可降低眼压,提高视力,降低血清VEGF、ET-1水平。Objective To investigate the clinical short-term efficacy of calcium dobesilate combined with laser and conbercept in the treatment of acute neovascular glaucoma and its influences on the expression of serum vascular endothelial growth factor(VEGF)and endothelin-1(ET-1).Methods This was a randomized controlled study.A total of 80 cases with acute neovascular glaucoma in Xinyang Central Hospital from Jan.2020 to Dec.2021 were selected and all cases divided into control group and observation group,according to random number table method,with 40 cases in each group.The control group received iris laser and panretinal photocoagulation combined with intravitreal injection of conbercept,and the observation group were treated with oral calcium dobesilate on the basis of the treatment of the control group.The changes of peripheral anterior chamber depth,intraocular pressure and visual acuity in both groups were compared.The follow-up period was 3 months.Results After treatment,the peripheral anterior chamber depth,intraocular pressure and visual acuity in both groups were better than before treatment(all P<0.05).After 1 and 3 months treatment,the peripheral anterior chamber depth in the observation group was higher than that in the control group(t=2.26,2.05;all P<0.05),the intraocular pressure was lower than that in the control group(t=11.63,7.38;all P<0.05),and the visual acuity was better than that in the control group(t=2.63,5.06;all P<0.05).The total effective rate in the observation group was 87.50%(35/40),which was higher than that in the control group 67.50%(27/40)(χ^(2)=4.59,P=0.032).After treatment,the serum VEGF and ET-1 levels in 2 groups were lower than those before treatment(all P<0.05).After 1 and 3 months treatment,the serum VEGF level in the observation group was lower than that in the control group(all P<0.05),and the serum ET-1 level was lower than that in the control group(all P<0.05).The incidence of complications(12.50%vs 7.50%)was not significantly different between the control group and the observ

关 键 词：青光眼 新生血管性 钙 羟苯磺酸 康柏西普 激光 因子 生长 血管内皮 内皮素-1 

分 类 号：R775[医药卫生—眼科]